Pub Date : 2023-12-01Epub Date: 2023-06-23DOI: 10.1007/s12070-023-03986-w
S R Priya, Mitali Dandekar, Peter Paul, Chandra Shekhar Dravid, Abhishek Anand, Shekhar Keshri
Radiology has always been an important component in the evaluation of patients with head and neck cancers. Images that are appropriately acquired and systematically interpreted provide comprehensive information on local, regional, and distant disease extent. This impacts treatment decisions for primary or recurrent disease, and aids in prognostication and patient counselling. The recent significant advances in technology and instrumentation for treatment of head neck cancers have taken place in parallel with an increasing sophistication in radiodiagnostic systems. This is especially true for laryngeal neoplasms where there is now greater focus on functional outcomes and personalised treatment, thus expanding the scope and value of imaging.
Purpose: To formulate evidence-based guidelines on imaging for cancers of the larynx, from diagnosis and staging to monitoring of disease control after completion of treatment.
Methods and materials: A multidisciplinary analysis of current guidelines and published studies on the topic was performed.
Results: On the basis of evidence gathered, guidelines were drawn up; optimal suggestions were included for low-resource situations.
Conclusion: These guidelines are intended as an aid to all clinicians dealing with patients of laryngeal cancers. It is hoped that these will be instrumental in facilitating patient care, and in improving outcomes.
{"title":"Imaging for Laryngeal Malignancies: Guidelines for Clinicians.","authors":"S R Priya, Mitali Dandekar, Peter Paul, Chandra Shekhar Dravid, Abhishek Anand, Shekhar Keshri","doi":"10.1007/s12070-023-03986-w","DOIUrl":"10.1007/s12070-023-03986-w","url":null,"abstract":"<p><p>Radiology has always been an important component in the evaluation of patients with head and neck cancers. Images that are appropriately acquired and systematically interpreted provide comprehensive information on local, regional, and distant disease extent. This impacts treatment decisions for primary or recurrent disease, and aids in prognostication and patient counselling. The recent significant advances in technology and instrumentation for treatment of head neck cancers have taken place in parallel with an increasing sophistication in radiodiagnostic systems. This is especially true for laryngeal neoplasms where there is now greater focus on functional outcomes and personalised treatment, thus expanding the scope and value of imaging.</p><p><strong>Purpose: </strong>To formulate evidence-based guidelines on imaging for cancers of the larynx, from diagnosis and staging to monitoring of disease control after completion of treatment.</p><p><strong>Methods and materials: </strong>A multidisciplinary analysis of current guidelines and published studies on the topic was performed.</p><p><strong>Results: </strong>On the basis of evidence gathered, guidelines were drawn up; optimal suggestions were included for low-resource situations.</p><p><strong>Conclusion: </strong>These guidelines are intended as an aid to all clinicians dealing with patients of laryngeal cancers. It is hoped that these will be instrumental in facilitating patient care, and in improving outcomes.</p>","PeriodicalId":73898,"journal":{"name":"Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","volume":"32 1","pages":"3386-3395"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72951590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Issue Information","authors":"","doi":"10.1002/mar.21682","DOIUrl":"https://doi.org/10.1002/mar.21682","url":null,"abstract":"","PeriodicalId":73898,"journal":{"name":"Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44506496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-10eCollection Date: 2022-01-01DOI: 10.1155/2022/9635075
Yi Bai, Hao Wu, Jinrui Zhang, Sai Zhang, Zhixin Zhang, Hao Wang, Yamin Zhang, Zhongyang Shen
Biliary complications are currently one of the leading causes of liver failure and patient death after liver transplantation and need to be solved urgently. Biliary ischemia-reperfusion injury (IRI) is one of the important causes of biliary complications. IL-22 has a protective effect on liver injury and hepatitis diseases, and its safety and efficacy in the treatment of hepatitis have also been proved in human clinical experiments. Furthermore, multiple studies have confirmed that IL-22 promotes the proliferation and repair of epithelial cells in various organs. Still, its function in the bile duct after transplantation has not been explored. This study was aimed at investigating the effects of IL-22 on cholangiocyte IRI in vitro and in vivo and exploring its underlying mechanisms. We simulated the hypoxia process of bile duct epithelial cells through in vitro experiments to investigate the protective function and molecular mechanism of IL-22 on bile duct epithelial cells. Subsequently, the function and mechanism of IL-22 in the biliary IRI model of autologous orthotopic liver transplantation in rats were assessed. This study confirmed that IL-22 could promote cholangiocyte proliferation, decrease the apoptosis rate of cholangiocytes and tissues, decrease MDA levels, and increase SOD levels by activating STAT3. In addition, IL-22 can also reduce the level of mitochondrial membrane depolarization, protect mitochondria, reduce ROS production, and play a role in protecting bile ducts. These findings provide evidence for IL-22 as a novel and effective treatment for biliary IRI after liver transplantation.
{"title":"IL-22 Protects against Biliary Ischemia-Reperfusion Injury after Liver Transplantation via Activating STAT3 and Reducing Apoptosis and Oxidative Stress Levels In Vitro and In Vivo.","authors":"Yi Bai, Hao Wu, Jinrui Zhang, Sai Zhang, Zhixin Zhang, Hao Wang, Yamin Zhang, Zhongyang Shen","doi":"10.1155/2022/9635075","DOIUrl":"10.1155/2022/9635075","url":null,"abstract":"<p><p>Biliary complications are currently one of the leading causes of liver failure and patient death after liver transplantation and need to be solved urgently. Biliary ischemia-reperfusion injury (IRI) is one of the important causes of biliary complications. IL-22 has a protective effect on liver injury and hepatitis diseases, and its safety and efficacy in the treatment of hepatitis have also been proved in human clinical experiments. Furthermore, multiple studies have confirmed that IL-22 promotes the proliferation and repair of epithelial cells in various organs. Still, its function in the bile duct after transplantation has not been explored. This study was aimed at investigating the effects of IL-22 on cholangiocyte IRI in vitro and in vivo and exploring its underlying mechanisms. We simulated the hypoxia process of bile duct epithelial cells through in vitro experiments to investigate the protective function and molecular mechanism of IL-22 on bile duct epithelial cells. Subsequently, the function and mechanism of IL-22 in the biliary IRI model of autologous orthotopic liver transplantation in rats were assessed. This study confirmed that IL-22 could promote cholangiocyte proliferation, decrease the apoptosis rate of cholangiocytes and tissues, decrease MDA levels, and increase SOD levels by activating STAT3. In addition, IL-22 can also reduce the level of mitochondrial membrane depolarization, protect mitochondria, reduce ROS production, and play a role in protecting bile ducts. These findings provide evidence for IL-22 as a novel and effective treatment for biliary IRI after liver transplantation.</p>","PeriodicalId":73898,"journal":{"name":"Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","volume":"34 1","pages":"9635075"},"PeriodicalIF":0.0,"publicationDate":"2022-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72960607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-06-01DOI: 10.1002/j.2055-2335.2013.tb00895.x
{"title":"Chapter 1: Medication Reconciliation","authors":"","doi":"10.1002/j.2055-2335.2013.tb00895.x","DOIUrl":"https://doi.org/10.1002/j.2055-2335.2013.tb00895.x","url":null,"abstract":"","PeriodicalId":73898,"journal":{"name":"Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.2055-2335.2013.tb00895.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50724414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-06-01DOI: 10.1002/j.2055-2335.2013.tb00902.x
{"title":"Chapter 8: Prioritising Clinical Pharmacy Services","authors":"","doi":"10.1002/j.2055-2335.2013.tb00902.x","DOIUrl":"https://doi.org/10.1002/j.2055-2335.2013.tb00902.x","url":null,"abstract":"","PeriodicalId":73898,"journal":{"name":"Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","volume":"298 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.2055-2335.2013.tb00902.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50724581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-06-01DOI: 10.1002/j.2055-2335.2013.tb00903.x
{"title":"Chapter 9: Staffing Levels and Structure for the Provision of Clinical Pharmacy Services","authors":"","doi":"10.1002/j.2055-2335.2013.tb00903.x","DOIUrl":"https://doi.org/10.1002/j.2055-2335.2013.tb00903.x","url":null,"abstract":"","PeriodicalId":73898,"journal":{"name":"Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","volume":"288 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.2055-2335.2013.tb00903.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50724591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-06-01DOI: 10.1002/j.2055-2335.2013.tb00898.x
{"title":"Chapter 4: Medication Management Plan","authors":"","doi":"10.1002/j.2055-2335.2013.tb00898.x","DOIUrl":"https://doi.org/10.1002/j.2055-2335.2013.tb00898.x","url":null,"abstract":"","PeriodicalId":73898,"journal":{"name":"Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","volume":"38 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.2055-2335.2013.tb00898.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50724491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-06-01DOI: 10.1002/j.2055-2335.2013.tb00894.x
G. Taylor, A. Leversha, C. Archer, C. Boland, M. Dooley, P. Fowler, Sharon Gordon-Croal, J. Fitch, S. Marotti, Amy McKenzie, Duncan McKenzie, Natalie Collard, Nicki Burridge, K. O’Leary, C. Randall, A. Roberts, S. Seaton
SHPA Committee of Speciality Practice in Clinical Pharmacy. George Taylor (Chair), Anne Leversha, Christopher Archer, Camille Boland, Michael Dooley, Peter Fowler, Sharon Gordon-Croal, Jay Fitch, Sally Marotti, Amy McKenzie, Duncan McKenzie, Natalie Collard, Nicki Burridge, Karen OLeary, Cameron Randall, Amber Roberts, Suzette Seaton Corresponding author: George Taylor, Clinical Lecturer, School of Pharmacy, University of Tasmania, Hobart Tas. 7001, Australia. E-mail: G.Taylor@utas.edu.au INTRODUCTION These standards supersede the previously published SHPA Standards of Practice for Clinical Pharmacy and SHPA Standards of Practice for the Provision of Medication Reconciliation. The practice of clinical pharmacy continues to evolve with the changing needs and demands of contemporary health care. These standards are applicable to the delivery of clinical pharmacy services across all care settings: inpatients, outpatients and patients in the community. They describe the activities delivered by pharmacists for patients to minimise the risks associated with the use of medicines and to optimise the use of medicines. Comprehensive and accountable clinical pharmacy services are an essential component of contemporary health care. Ideally, every health service organisation will have resources to provide all clinical pharmacy activities to every patient based on their needs. Australian and overseas practice-based evidence con! rm that the pharmacist activities described in these standards support an individual patients medication management plan (MMP) and reduce morbidity, mortality and the cost of care. Clinical pharmacy services for individual patients support the objectives of: Guiding Principles to Achieve Continuity in Medication Management National Safety and Quality Health Service Standards Australian Safety and Quality Goals for Health Care Hospital Accreditation Workbook National Strategy for Quality Use of Medicines Medication Safety Self-Assessment for Australian Hospitals Antimicrobial Stewardship in Australian Hospitals. In addition, clinical pharmacy services for individual patients enable the objectives of national strategies to improve patient safety and quality of care to be met, such as: Patient-Centred Care: Improving Quality and Safety through Partnerships with Patients and Consumers Match Up Medicines: A Guide to Medication Reconciliation National Inpatient Medication Chart (NIMC), National Aged Care Residential Medication Chart, Paediatric Medication Chart, Private Hospital NIMC and Private Hospital Day Surgery NIMC National Medication Management Plan Australian Charter of Healthcare Rights OSSIE Guide to Clinical Handover Improvement. Other SHPA standards of practice and guidelines in specialty areas should be read in conjunction with these standards including: Standards of Practice for Medication Safety Standards of Practice for Drug Use Evaluation in Australian Hospitals Standards of Practice for the
{"title":"Overview: Standards of Practice for Clinical Pharmacy Services","authors":"G. Taylor, A. Leversha, C. Archer, C. Boland, M. Dooley, P. Fowler, Sharon Gordon-Croal, J. Fitch, S. Marotti, Amy McKenzie, Duncan McKenzie, Natalie Collard, Nicki Burridge, K. O’Leary, C. Randall, A. Roberts, S. Seaton","doi":"10.1002/j.2055-2335.2013.tb00894.x","DOIUrl":"https://doi.org/10.1002/j.2055-2335.2013.tb00894.x","url":null,"abstract":"SHPA Committee of Speciality Practice in Clinical Pharmacy. George Taylor (Chair), Anne Leversha, Christopher Archer, Camille Boland, Michael Dooley, Peter Fowler, Sharon Gordon-Croal, Jay Fitch, Sally Marotti, Amy McKenzie, Duncan McKenzie, Natalie Collard, Nicki Burridge, Karen OLeary, Cameron Randall, Amber Roberts, Suzette Seaton Corresponding author: George Taylor, Clinical Lecturer, School of Pharmacy, University of Tasmania, Hobart Tas. 7001, Australia. E-mail: G.Taylor@utas.edu.au INTRODUCTION These standards supersede the previously published SHPA Standards of Practice for Clinical Pharmacy and SHPA Standards of Practice for the Provision of Medication Reconciliation. The practice of clinical pharmacy continues to evolve with the changing needs and demands of contemporary health care. These standards are applicable to the delivery of clinical pharmacy services across all care settings: inpatients, outpatients and patients in the community. They describe the activities delivered by pharmacists for patients to minimise the risks associated with the use of medicines and to optimise the use of medicines. Comprehensive and accountable clinical pharmacy services are an essential component of contemporary health care. Ideally, every health service organisation will have resources to provide all clinical pharmacy activities to every patient based on their needs. Australian and overseas practice-based evidence con! rm that the pharmacist activities described in these standards support an individual patients medication management plan (MMP) and reduce morbidity, mortality and the cost of care. Clinical pharmacy services for individual patients support the objectives of: Guiding Principles to Achieve Continuity in Medication Management National Safety and Quality Health Service Standards Australian Safety and Quality Goals for Health Care Hospital Accreditation Workbook National Strategy for Quality Use of Medicines Medication Safety Self-Assessment for Australian Hospitals Antimicrobial Stewardship in Australian Hospitals. In addition, clinical pharmacy services for individual patients enable the objectives of national strategies to improve patient safety and quality of care to be met, such as: Patient-Centred Care: Improving Quality and Safety through Partnerships with Patients and Consumers Match Up Medicines: A Guide to Medication Reconciliation National Inpatient Medication Chart (NIMC), National Aged Care Residential Medication Chart, Paediatric Medication Chart, Private Hospital NIMC and Private Hospital Day Surgery NIMC National Medication Management Plan Australian Charter of Healthcare Rights OSSIE Guide to Clinical Handover Improvement. Other SHPA standards of practice and guidelines in specialty areas should be read in conjunction with these standards including: Standards of Practice for Medication Safety Standards of Practice for Drug Use Evaluation in Australian Hospitals Standards of Practice for the","PeriodicalId":73898,"journal":{"name":"Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.2055-2335.2013.tb00894.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50724856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-06-01DOI: 10.1002/j.2055-2335.2013.tb00897.x
G. Taylor, A. Leversha, C. Archer, C. Boland, M. Dooley, P. Fowler, Sharon Gordon-Croal, J. Fitch, S. Marotti, Amy McKenzie, Duncan McKenzie, Natalie Collard, Nicki Burridge, K. O’Leary, C. Randall, A. Roberts, S. Seaton
INTRODUCTION Clinical review, therapeutic drug monitoring (TDM) and adverse drug reaction (ADR) management contribute to the quality use of medicines by ensuring safe and appropriate dosage and administration of medicines, improving response to therapy and minimising medicinesrelated problems. Clinical review, TDM and ADR management commence when a patient presents or is admitted to a health service organisation and continue as routine activities throughout the episode of care in conjunction with assessment of current medication management and other clinical pharmacy activities.
{"title":"Chapter 3: Clinical Review, Therapeutic Drug Monitoring and Adverse Drug Reaction Management","authors":"G. Taylor, A. Leversha, C. Archer, C. Boland, M. Dooley, P. Fowler, Sharon Gordon-Croal, J. Fitch, S. Marotti, Amy McKenzie, Duncan McKenzie, Natalie Collard, Nicki Burridge, K. O’Leary, C. Randall, A. Roberts, S. Seaton","doi":"10.1002/j.2055-2335.2013.tb00897.x","DOIUrl":"https://doi.org/10.1002/j.2055-2335.2013.tb00897.x","url":null,"abstract":"INTRODUCTION Clinical review, therapeutic drug monitoring (TDM) and adverse drug reaction (ADR) management contribute to the quality use of medicines by ensuring safe and appropriate dosage and administration of medicines, improving response to therapy and minimising medicinesrelated problems. Clinical review, TDM and ADR management commence when a patient presents or is admitted to a health service organisation and continue as routine activities throughout the episode of care in conjunction with assessment of current medication management and other clinical pharmacy activities.","PeriodicalId":73898,"journal":{"name":"Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","volume":"39 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.2055-2335.2013.tb00897.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50724439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-06-01DOI: 10.1002/j.2055-2335.2013.tb00896.x
INTRODUCTION Assessment of a patient’s current medication management is vital to ensure the quality use of medicines. The assessment aims to optimise the quality use of medicines and therefore patient outcomes, and to minimise medicines-related problems. To assess the patient’s current medication management, the pharmacist confi rms the safety and appropriateness of individual medication orders and the combination of medicines prescribed. This assessment is then documented in the patient’s record or the pharmacy section of the National Inpatient Medication Chart (NIMC) or equivalent. Assessment of a patient’s current medication management should not be done in isolation. It requires a systematic, in-depth assessment of current medicines in consultation with the patient taking into account: • the patient’s medication history • the patient’s medication management plan (MMP) and data from the medication administration record • a clinical review including therapeutic drug monitoring (TDM).
{"title":"Chapter 2: Assessment of Current Medication Management","authors":"","doi":"10.1002/j.2055-2335.2013.tb00896.x","DOIUrl":"https://doi.org/10.1002/j.2055-2335.2013.tb00896.x","url":null,"abstract":"INTRODUCTION Assessment of a patient’s current medication management is vital to ensure the quality use of medicines. The assessment aims to optimise the quality use of medicines and therefore patient outcomes, and to minimise medicines-related problems. To assess the patient’s current medication management, the pharmacist confi rms the safety and appropriateness of individual medication orders and the combination of medicines prescribed. This assessment is then documented in the patient’s record or the pharmacy section of the National Inpatient Medication Chart (NIMC) or equivalent. Assessment of a patient’s current medication management should not be done in isolation. It requires a systematic, in-depth assessment of current medicines in consultation with the patient taking into account: • the patient’s medication history • the patient’s medication management plan (MMP) and data from the medication administration record • a clinical review including therapeutic drug monitoring (TDM).","PeriodicalId":73898,"journal":{"name":"Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","volume":"40 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.2055-2335.2013.tb00896.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50724426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号